Search clinical trials for: Phosphatidylinositol 3-kinase inhibitor

Total 67669 results

Murdoch Childrens Research Institute
Royal Children's Hospital; Peter MacCallum Cancer Centre, Australia

Not yet recruiting

A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations (TARGET-VM)

Arteriovenous Malformations | Vascular Malformations | MAP2K1 Gene Mutation | PIK3CA-related Overgrowth Spectrum | Vascular Anomalies | Lymphangioma | Lymphatic Malformation | KRAS G12D | Venous Malformation | Vascular Anomaly | KRAS G12C | PI3K Gene Mutation | Slow-Flow Vascular Malformation | Fast-Flow Vascular... and other conditions

Australia
Hutchison Medipharma Limited

Recruiting

Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

Follicular Lymphoma | Marginal Zone Lymphoma

China
Incyte Corporation

Recruiting

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

B-Cell Malignancies

United States, Spain, Belgium, Japan, Italy, France, United Kingdom, Israel, Turkey, Norway, Korea, Republic of, Czechia, Sweden, Austria, Poland, Hungary, Denmark
University of California, San Francisco
Novartis Pharmaceuticals; Pediatric Brain Tumor Foundation; The Lilabean Foundation...

Recruiting

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

High Grade Glioma | Low-grade Glioma | Recurrent World Health Organization (WHO) Grade II Glioma

United States
Incyte Corporation

Completed

A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia

Autoimmune Hemolytic Anemia

United States, France, Italy, Austria
Ludwig-Maximilians - University of Munich
Bayer; Roche Pharma AG

Active, not recruiting

A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden (Alternative-C)

Follicular Lymphoma

Germany
Incyte Corporation

Active, not recruiting

A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

Lymphoma

Belgium, United States, France, Israel, Italy, United Kingdom, Germany, Spain, Poland, Australia, Argentina, Denmark
Incyte Corporation

Active, not recruiting

A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

Lymphoma

United States, Spain, Italy, Israel, Poland, United Kingdom, Canada, Czechia, Germany, Denmark, Australia, Hungary, Sweden
Bayer

Terminated

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) (CHRONOS-4)

Lymphoma, Non-Hodgkin

United States, Hungary, China, Belgium, Korea, Republic of, France, Australia, Russian Federation, Taiwan, Denmark, Japan, United Kingdom, Spain, South Africa, Turkey, Romania, Singapore, Israel, Ireland, Canada, Poland, Greece, Cze... and more
Incyte Corporation

Active, not recruiting

A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor ((CITADEL-205))

Lymphoma

United States, Spain, France, United Kingdom, Czechia, Israel, Belgium, Italy, Germany, Poland, Denmark
GlaxoSmithKline

Completed

Phase 1, Single and Repeat Dose Study to Assess Safety, Tolerability, and Pharmacokinetics (PK) of GSK3923868 in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany
Bayer

Completed

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

Lymphoma, Non-Hodgkin

Belgium, France, Spain, Hong Kong, Turkey, Russian Federation, Singapore, United States, Canada, Germany, Australia, New Zealand, Finland, Austria, United Kingdom, Bulgaria, Hungary, Italy, Israel, Korea, Republic of, Poland, Port... and more
Incyte Corporation

Completed

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

B-cell Lymphoma

United States, Spain, Italy
Incyte Corporation

Completed

A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)

Lymphoma

United States, Spain, Korea, Republic of, Belgium, Australia, Czechia, Poland, Canada, France, Italy, United Kingdom
Gilead Sciences

Completed

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Indolent Non-Hodgkin's Lymphoma

United States
Novartis Pharmaceuticals

Completed

A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer

Breast Cancer | Solid Tumors | Cowden Syndrome

United States, Spain, Canada
Novartis Pharmaceuticals

Completed

A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer

Breast Cancer | Advanced Solid Tumors | Cowden Syndrome

Netherlands, Spain, Germany, United Kingdom, United States
Incyte Corporation

Completed

A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma

Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

United States
PIQUR Therapeutics AG
Royal Marsden NHS Foundation Trust; University College London Hospitals; Weill... and other collaborators

Completed

Open-Label, Non Randomized Phase 2 Study With Safety Run-In

Lymphoma, Malignant

United States, United Kingdom, Serbia, Bosnia and Herzegovina, France, Israel
Gilead Sciences

Terminated

An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study

Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia

United States
Gilead Sciences

Completed

Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas (DELTA)

Follicular Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Small Lymphocytic Lymphoma

United States, United Kingdom, Italy, Germany, Poland, France
PIQUR Therapeutics AG
Charite University, Berlin, Germany; University Hospital, Basel, Switzerland; University Hospital Freiburg and other collaborators

Completed

Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients

Lymphoma | Non-Hodgkin Lymphoma

Germany
Gilead Sciences

Completed

Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma

Follicular Lymphoma | Marginal Zone Lymphoma | Small Lymphocytic Lymphoma | Indolent Non-Hodgkin's Lymphoma

United States
Gilead Sciences

Terminated

A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
Gilead Sciences

Completed

Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber

Allergic Rhinitis

Austria
Bayer

Completed

Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer

Neoplasms

United States
Bayer

Completed

Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer

Neoplasms

United States
Dana-Farber Cancer Institute
Gilead Sciences

Terminated

Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia

Waldenstrom's Macroglobulinemia

United States
M.D. Anderson Cancer Center

Terminated

Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients

Advanced Cancers

United States
Peking University People's Hospital
Beijing Hospital

Unknown

Combination of Ibrutinib and As2O3 in the Treatment of CLL

Leukemia, Lymphocytic, Chronic, B-Cell
Mario Negri Institute for Pharmacological Research

Completed

Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND)

Type 2 Diabetes

Italy, Slovenia
Gilead Sciences

Completed

Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies

Chronic Lymphocytic Leukemia (CLL) | Acute Myeloid Leukemia (AML) | Multiple Myeloma (MM) | Lymphoma, Non-Hodgkin (NHL)

United States
The First Affiliated Hospital of Soochow University

Not yet recruiting

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Multiple Myeloma | Newly Diagnosed | MRD | High Risk
Bruno Minotti
Roland Bingisser, Principal Investigator, Head of Emergency Department, University... and other collaborators

Not yet recruiting

Open-Label Placebo for Non-Specific Pain in the ED (OLP_EM)

Pain, Acute
M.D. Anderson Cancer Center

Not yet recruiting

Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)

Hormone Receptor-positive Human Epidermal Growth Factor 2-negative | Metastatic Invasive LObular Carcinoma

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto
Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica

Not yet recruiting

PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML (PEARL)

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, Chronic Phase | CML, Chronic Phase | Chronic Myeloid Leukemia, BCR/ABL-Positive
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer

Liver Cancer
University Hospital, Basel, Switzerland

Not yet recruiting

Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors (ISCA-CHECK)

Advanced Solid Tumor

Switzerland
Lionel.D.Lewis, MD
Dartmouth Cancer Center

Not yet recruiting

HCQ in Resectable Localized Prostate Cancer

Resectable Localized Prostate Cancer
Stanford University

Not yet recruiting

Stanford and University of Illinois Chicago ACE-D Study (ACE-D)

Depression

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation

Liver Cancer | Liver Transplant

China
University of Pennsylvania
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Not yet recruiting

APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia (APPLE)

Pre-Eclampsia | Pregnancy Loss

United States
AstraZeneca
Parexel

Not yet recruiting

Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).

Opioid Use Disorder

United States
University of Wisconsin, Madison
Merck Sharp & Dohme LLC

Not yet recruiting

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

Kidney Transplant Infection | Cytomegalovirus Infections | Pancreas Transplant

United States
Tel Aviv Medical Center

Not yet recruiting

Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer

Triple Negative Breast Cancer
Hanoi Medical University

Recruiting

Treatment Result of Zirconia Laminate Veneer

Tooth Abnormalities | Tooth Injuries | Teeth, Endodontically-Treated | Tooth Fracture | Tooth Crowding | Dislocation, Tooth | Cracked Tooth Syndrome

Vietnam
Teeradon Waewworawit

Not yet recruiting

Efficacy of Intra-Articular Corticosteroid Injections on Clinical Outcomes in Patients With Operative Distal Radius Fractures

Wrist Fractures | Intraarticular Injection
National Cancer Institute (NCI)

Not yet recruiting

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Carcinoma, Neuroendocrine | Tumor, Neuroendocrine | Tumors, Neuroendocrine | Neuroendocrine; Carcinoma | Small Cell; Receptors

United States
Henan Cancer Hospital

Recruiting

A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung Cancer

Extensive Small Cell Lung Cancer

China
European Organisation for Research and Treatment...

Not yet recruiting

Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Women With Early Breast Cancer; A Pragmatic Randomized Controlled Trial

Musculoskeletal Pain | Drug-Related Side Effects and Adverse Reactions | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | HER2-negative Breast Cancer | ER+ Breast Cancer

Search clinical trials for: Phosphatidylinositol 3-kinase inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations